The U.S. Food and Drug Administration rejects ivonescimab, a lung cancer drug developed in China, according to reports. The decision comes after the treatment drew close attention as it moved through U.S. review.
Both outlets frame the rejection as a test of whether China’s growing drug-development efforts can meet U.S. standards. The New York Times describes ivonescimab as a symbol of China’s rise in drug development, while the Financial Times emphasizes its impact on Beijing’s biotech sector and the broader implications for future Chinese medicine entering the U.S. market. Across the coverage, the shared focus is that the drug’s failure represents a setback for the company behind it and for expectations built around the review process.
